Hengrui Pharma Signs Licensing Deal to Sell Cancer Drug in India

Jiangsu Hengrui Pharmaceuticals Co. Ltd. (600276.SH) has partnered with Dr. Reddy’s Laboratories Ltd. to promote its oral breast cancer treatment in India, becoming the latest tie-up between Chinese and foreign drugmakers as the former further expands into lucrative overseas markets.

Hengrui, one of China’s largest innovative drug developers, said Sunday that it has signed an agreement with the India-based drugmaker granting it exclusive rights to develop and commercialize Hengrui’s self-developed Pyrotinib Maleate Tablets, or Pyrotinib in short, in the South Asian country.